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We examined 11 cases of carcinoma arising from Barrett’s esophagus consisting of  
two adenocarcinomas in situ (ACIS), two intramucosal adenocarcinomas, and seven 
overt invasive adenocarcinomas, and measured overexpression of p53 (implying a 
mutation of the p53 gene), ERBB2, and EGFR by immunohistochemistry, and measured 
gene amplification of ERBB2 and EGFR by fluorescence in situ hybridization (FISH). 
In all the cases of ACIS and the intramucosal adenocarcinomas, almost all cancer cells 
overexpressed p53, however the populations overexpressing of ERBB2 and EGFR 
varied in different cases: in one ACIS ERBB2 was coexpressed in all the cancer cells, in 
the other ACIS and the one intramucosal adenocarcinoma, ERBB2 was overexpressed 
in about 50% and only 10% of the p53-positive cells respectively, and EGFR was 
co-expressed in 50% in the other intramucosal adenocarcinoma. Protein overexpression 
of ERBB2 or EGFR corresponded to the amplification of their respective genes on a 
cell by cell basis. These gene amplifications, however, were not found in the seven 
invasive adenocarcinomas. Thus we speculate that the gene amplification occurred late 
in dysplasia-carcinoma sequence probably after the mutation of p53. Furthermore, new 
clonal expansion accompanied by tumor invasion might have extinguished the 
originally amplified genes in these tumors. 
 




Esophageal adenocarcinomas are thought to develop in columnar-lined Barrett’s 
esophagus 1. Progression from the metaplastic columnar epithelium of Barrett’s 
esophagus through dysplastic changes to adenocarcinoma most likely entails a series of 
genetic alterations. The molecular alterations that have been detected in the course of 
the dysplasia-adenocarcinoma sequence include mutations and overexpression of p53 2, 
and/or amplification and overexpression of ERBB2 3, EGFR, or MYC 4. Recently, 
array-based comparative genomic hybridization (aCGH) or single nucleotide 
polymorphism (SNP) array have detected novel candidate genes involved in 
development and progression of Barrett’s carcinoma. Among them, SOX7 5and SNRPN 6 
were identified as the most frequently amplified genes by two groups respectively. 
Clinically, the treatment of dysplasia in Barrett’s esophagus ranges from close 
monitoring to surgical excision, mainly depending on the interpretation of the grade of 
the dysplasia 7, 8. Although some have argued that finding high-grade dysplasia upon 
repeat biopsy is a possible indication for surgery 9, occasionally there is significant 
morbidity associated with esophagectomy 10. Thus the diagnosis of dysplasia and 
adenocarcinoma in situ (ACIS) of Barrett’s esophagus is a heavy decision. Furthermore, 
the diagnosis of dysplasia and its grade are subjective 11, and unfortunately there are 
many interobserver differences in diagnoses. Although various approaches such as 
mucin histochemistry, flow cytometry, immunohistochemistry (IHC), and molecular 
biology have been tried 12-17； to help in this difficult decision, no objective and 
practical adjunct to routine histologic diagnosis has been established. 
In Japan, Barrett’s esophagus and esophageal adenocarcinoma are less common than 
in Western countries. This is in sharp contrast to the high frequency of gastric 
adenocarcinomas. In recent years, however, there has been a gradual increase in the 
detection of both Barrett’s esophagus and esophageal adenocarcinomas, although the 
incidences of these conditions remain considerably lower than in Western countries 18. 
Recently, we had an opportunity to diagnose a case of ACIS of Barrett’s esophagus 
confidently by biopsy specimen with the detection of ERBB2 amplification using 
fluorescence in situ hybridization (FISH). To understand the significance of this finding, 
we searched the surgical pathology file of the Pathology Section of Kanazawa 
University Hospital and retrieved ten adenocarcinomas arising from Barrett’s esophagus, 
and examined the amplification of ERBB2, as well as EGFR, MYC, SOX7 and SNRPN, 




Materials and methods 
 
The first case (case 1) was a 70-year-old Japanese man who had an open ulcer in a 
Barrett’s esophagus. The diagnosis of previous biopsies was regenerating mucosa with 
moderate atypia. The biopsy specimen taken around the ulcer was resubmitted, and a 
diagnosis of “ACIS” was made. After a thorough analysis of this case, we searched the 
surgical pathology files of the Pathology Section of Kanazawa University Hospital 
between 2005 and 2008 for cases of adenocarcinoma of distal esophagus, 
adenocarcinoma of gastroesophageal junction (GEJ), and Barrett’s mucosa. Only 12 
cases were found despite the fact that more than 400 gastric adenocarcinomas were 
registered in this period. Of the 12 cases, six esophagectomy and four endoscopic 
mucosal resection/submucosal dissection (EMR/ESD) specimens (cases 2- 11) (Table 1) 
were retrieved as adenocarcinomas arising in Barrett’s esophagus, because the 
metaplastic epithelium (columnar epithelium with goblet cells) was histologically 
confirmed above the macroscopically identified GEJ.  
No patients had received radiation or chemotherapy before surgery except case 11 
who received pre-operative chemotherapy. This laboratory study using these specimens 
was approved by the Institutional Review Board at the Kanazawa University, and 
written informed consent was obtained from all patients. 
 
Diagnoses and grading 
The depth of invasion of adenocarcinomas was defined according to the cancer 
staging manual of the American Joint Committee on Cancer 19. “ACIS” was defined 
synonymously with severe dysplasia 9, 10, and “intramucosal carcinoma” was defined as 
a carcinoma that has penetrated through the basement membrane of the glands into the 
lamina propria but has not yet invaded through the muscularis mucosae into the 
submucosa 20. According to these criteria the hematoxylin-eosin staining slides were 
reviewed by the three pathologists (AO, YZ and SS). 
 
IHC 
Serial sections (4 μm) cut from representative formalin-fixed, paraffin-embedded 
tissues and placed onto MASTM-coated slides (Matsunami, Tokyo, Japan) were used for 
IHC detection and FISH analysis. A monoclonal antibody against the recombinant 
human wild-type p53 (DO-7, Dako, Glostrup, Denmark), a polyclonal antibody against 
the internal domain of the human ERBB2 protein (Nichirei, Tokyo, Japan; working 
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dilution, 1:100), and a monoclonal antibody against the internal domain of human 
EGFR (Novocastra Lab, Newcastle, UK; working dilution, 1:20) were used. For the 
detection of p53 and EGFR, a high-temperature antigen unmasking technique was used. 
IHC was done using an ELSBTM 2 System (Dako) and visualized with 
3,3’-diaminobenzidine. 
For the evaluation of ERBB2 and EGFR positivities, each tumor or portion of tumor 
was scored according to the criteria recommended by Dako for the HercepTest. For an 
evaluation of p53 staining, only nuclear immunostaining significantly higher than that 
of the control cells of the normal esophageal mucosa were considered to be positive. 
 
FISH
FISH analyses of the gene amplification were applied to all tumors. For FISH probes, 
bacterial artificial chromosomes RP11-62N23, RP11-339F13, RP11-49I23 specific for 
ERBB2 locus (17q12), EGFR locus (7p12 ), and SOX7 locus (8p23.1) respectively, and 
P1 artificial chromosome clone RP1-80K22 specific for MYC locus (8q24.12-q24.13) 
were used. RP11-49I23 was available from BACPAC Resources (Oakland, CA, USA). 
These probes were labeled with SpectrumOrangeTM using a nick translation kit (Abbott, 
Abbott Park, IL, USA). In order to standardize the chromosome number a 
SpectrumGreenTM-labeled pericentromeric probe (Abbott), which was specific to the 
chromosome on which the gene was located, was cohybridized. SNRPN specific probe 
was purchased from VYSIS as microdeletion detecting kit (Tri Color Probe 1N12-10, 
SNRPN SpectrumOrangeTM/CEP15 SpectrumAquaTM/PML SpectrumGreenTM). FISH 
was performed using standard methods as described elsewhere 21. The tissue sections 
were counterstained with 4’,6-diamidine-2’-phenylindole dihydrochloride and 
p-phenylenediamine in phosphate-buffered saline and glycerol (DAPI II) (Abbott) and 
examined under a fluorescence microscope (Olympus, Tokyo, Japan) equipped with a 
Triple Bandpass FilterTM set (Abbott) to discriminate DAPI II, SpectrumOrangeTM, and 
SpectrumGreenTM , and a filter specific to SpectrumAquaTM. 
For the evaluation of gene amplification, each tumor was scored according to the 
criteria recommended by Abbott for PathVisionTM. A cell with a definite cluster of 
signals or a total of more than 10 signals was scored as exhibiting high-level 






The biopsy specimen taken around the ulcer (Fig. 1) showed intestinal-typed atypical 
epithelium highly suggestive of ACIS (Fig. 2A). By IHC, atypical cells were found to 
have p53-positive nuclei and ERBB2 2+ cytoplasmic membranes (Fig. 2B, C). FISH 
revealed that the ERBB2-positive cells had clustered signals of ERBB2 (Fig. 2D). No 
amplification of the EGFR and MYC by FISH was found. We diagnosed this as ACIS 
arising in a Barrett’s esophagus. After two weeks of medication for peptic ulcer, the 
lower 11 cm of the esophagus was resected (Fig. 3A). An ulcer scar interrupting the 
muscle coat was found 2.3 cm from the GEJ. The mucosa between the GEJ to 
squamocolumnar junction showed immature intestinal metaplasia with islands of 
squamous mucosa and esophageal glands. The mucosa measuring 2.5 ×2.3 cm 
surrounding the ulcer scar was finely granular. Histologically, corresponding to the 
granular mucosa, ACIS was found with patches of regenerating mucosa (Fig. 3B). No 
metastasis in regional lymph nodes was found. Identical to the results in biopsy 
specimen, almost all adenocarcinoma cells were positive for both p53 and ERBB2 (Fig 
3C), and were amplified for ERBB2 (Fig. 3D). No amplification of EGFR, MYC, SOX2 
and SNRPN was found. 
 
Cases 2–11 
  By examining the slides of resected specimens, interobserver agreements was 
achieved in all the cases except case 2, for which the diagnosis was separated into ACIS 
and intramucosal adenocarcioma with limited infiltration to lamina propria mucosae by 
two versus one. We looked for overexpression of ERBB2, EGFR, and p53, and 
amplification of ERBB2, EGFR, MYC, SOX2 and SNRPN in these cases using resected 
specimens and biopsy specimens for which the diagnosis of adenocarcinoma was made. 
Parts of the results are summarized in Table 1. 
In case 2 and an intramucosal adenocarcinoma (case 3), almost all cancer cells were 
p53-positive (Fig. 4A) and approximately 50% and 10% of them were also positive for 
ERBB2 and occupied a part of the tumor (Fig. 4B&C). In FISH using the adjacent 
section, ERBB2-positive cells were found to have one or two clusters of numerous 
ERBB2 signals as shown in Fig. 4D. EGFR, MYC, SOX2 and SNRPN were not 
amplified.  
In case 4, the other case of intramucosal adenocarcinoma, although almost all cancer 
cells overexpressed p53, overexpression of EGFR was confined to only 20% of them 
and occupied a proximal area of the tumor (Fig. 5A–C). Corresponding to the protein 
overexpression, one or two clustered signals of EGFR were found by FISH (Fig. 5C, D). 
Neither ERBB2, MYC, SOX2, nor SNRPN were amplified. Comparing IHC and FISH 
 7
specimens, protein overexpression and gene amplification of ERBB2 and EGFR 
corresponded on a cell by cell basis respectively in cases 2 and 3 (Fig. 5C, D).  
By examining biopsy specimens in which diagnosis of adenocarcinoma was made 
retrospectively, amplification of ERBB2 and EGFR was found in case 2 and 4 
respectively, but amplification was not detected in case 3. In the seven advanced cancers, 
p53 was overexpressed in cases 5, 7, 8, and 11, however  overexpression of ERBB2 and  





It is now generally accepted that Barrett’s esophagus predisposes patients to 
esophageal adenocarcinomas 1. Early diagnosis of dysplasia or invasive 
adenocarcinoma is crucial for optimal treatment. However, concerning morphological 
recognition of dysplasia and occasionally adenocarcinoma, sometimes considerable 
interobserver- and intraobserver-variability exist. In an interobserver variability study 
performed by 12 pathologists, Montgomery et al. reported that majority diagnosis was 
not attained in 39 of 138 endoscopic biopsy specimens obtained from Barrett’s 
esophagus. As found in the present case, biopsy specimens taken from the edges of 
ulcers may be hardly distinguishable from dysplasia from reactive or regenerative 
hyperplasia 22. In another study of a blinded review of endoscopic biopsy specimens and 
samples of surgical specimens, fortunately the best inter-observer agreement among the 
eight participants averaged 86%, which was achieved in comparing the combinations of 
high grade dysplasia and intramucosal carcinoma with all other diagnoses (negative, 
indefinite, and low-grade dysplasia) 11. However, considering that esophagectomy may 
be decided by this diagnosis, this figure is not satisfactorily high. 
Overexpression of p53 protein detected immunohistochemically, implying a mutation 
in the p53 gene, has been reported in various neoplastic lesions of Barrett’s esophagus 
by a number of investigators 23. The present study also showed that p53 was 
overexpressed in all the four mucosal cancers. This suggests that p53 overexpression is 
a sensitive objective marker for dysplasia and adenocarcinoma. However, concerning its 
specificity to adenocarcinoma, there remains some problems because nuclear 
accumulation of p53 is as high in low-grade dysplastic lesions as in high-grade lesions 
or in adenocarcinomas 2. Furthermore, mutation and accumulation of p53 are frequently 
discordant in low-grade dysplasia, although they are mostly concordant in 
adenocarcinomas and high-grade dysplastic lesions 2. These results indicate that p53 
staining may have potential value for confirming a suspected diagnosis of a wide range 
of lesions from low grade dysplasia to more advanced lesions in the sequence. 
Amplification of ERBB2 (located on 17q11.2-q12 and 17q21.1) in Barrett’s 
esophagus and/or esophageal adenocarcinomas has been examined by Southern blotting 
14, differential PCR 14, 24, CGH25, or most recently SNP assay 5. However, FISH is the 
best method to detect gene amplification because one can define the genetic change on 
cell by cell basis as shown in the present study. Using FISH, Walch et al. found high 
grade dysplasia to be amplified for the ERBB2 locus; however, gene amplification was 
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not detected in low grade intraepithelial neoplasia, intestinal metaplasia, or squamous 
epithelium, indicating that the alteration of ERBB2 is a late event in the 
carcinonogenesis of Barrett’s esophagus 26. Our finding that p53-positive populations 
contained both ERBB2-positive and -negative populations, or EGFR-positive and 
-negative populations, strongly suggests that amplification of ERBB2 or EGFR in those 
tumors occurred after a missense mutation of the p53 gene. In our previous FISH study 
of adenocarcinomas of the stomach, similar to case 4 in the present study, we found a 
mucosal cancer in which p53-positive populations contained both EGFR-positive and 
-negative subpopulations 27. These studies suggest that karyotypic instability by 
loss-of-function of p53 precedes the associated amplification of ERBB2 or EGFR. In 
another FISH study, we found that MYC and ERBB2, and MYC and EGFR, were 
non-incidentally co-amplified in gastric adenocarcinoma 21. We recently reported on a 
mucosal adenocarcinoma of the gallbladder with two populations of tumor cells with 
the coexistence of amplified MYC and ERBB2, and MYC and EGFR 28. Thus we thought 
that amplification of MYC is another genetic alteration preceding FERBB2 or EGFR 
amplification; however, in the present study, amplification of MYC was not found.  
ERBB2 amplification was not found in the seven invasive adenocarcinomas. A CGH 
study comparing Barrett’s adenocarcinomas and their adjacent precursors detected an 
intriguing case, in which the amplicon of the cancer cells did not contain the ERBB2 
locus which was highly amplified in adjacent high grade dysplasia 25. This and our 
results may indicate that new clonal expansion accompanied by tumor invasion might 
have extinguished the originally amplified genes in these tumors, and the tumor 
becoming progressively more invasive do not require originally amplified ERBB2 or 
EGFR. However, further investigation of this hypothesis is needed. 
By aCGH Albrecht et al. detected most frequent copy number gain in Barrett’s 
adenocarcinoma was on 15q12, the SNRPN locus (61%), and they confirmed amplified 
SNRPN genes in single case by FISH6. More recently using SNP, Wiech at al. detected 
frequent copy number gain (26%) and the highest level of amplification on 8p23.1, the 
SOX7 locus5. Albrecht et al.6  also demonstrated a FISH picture showing SNRPN  
was involved in amplification. These prompted us to do FISH analysis of our cases 
using the DNA probes of the same sources of theirs. However, we could not detect the 
amplification of SNRPN or SOX7 in our cases. This could be explained by different 
sensitivity of array hybridization assay and FISH: in most amplification-positive tumors 
by the array assay the amplification level was so low that can be detected clearly by 
FISH. Alternatively this discrepancy may be due to racial difference between Japanese 
and Coucaisians 12because in the series of Wiech et al. the frequency of amplification of 
 10
ERBB2 locus was very low 5. However, although both the studies examined Coucasians 
patients, the frequent amplification of SNRPN was not detected in a series of Wiech et 
al.5, and to the contrary that of SOX7 was not found in the work of Albrecht et al. 6.Thus 
additional data seem to be necessary to resolve the discoｒdance 
Recently, instead of esophagectomy, less invasive therapies such as endoscopic 
ablation or mucosal resection have become available for the treatment of severe 
dysplasia/ACIS 29. In our case 1, however, we chose esophagectomy because the 
existence of an ulcer technically prevented EMR, and an ulcerated high-grade dysplasia 
is often a marker for adjunct invasive disease 10. In older debilitated patients who may 
not tolerate esophagectomy, amplification of ERBB2 or EGFR may be beneficial 
because molecularly targeted therapies against ERBB2 or EGFR could be another 
clinical option. The humanized monoclonal antibody, trastuzumab, is most effective in 
treatment of breast cancer with ERBB2 amplification. Now FISH tests for ERBB2 
amplification are becoming available even in diagnostic laboratories, and FISH probes 
for EGFR are also available commercially. Thus, FISH tests for gene amplification of 
ERBB2 and EGFR should be applied for biopsy specimens as an objective and practical 
adjunct to routine histologic diagnosis of adenocarcinoma of Barrett’s esophagus. 
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IHC     IHC FISH IHC FISH
1 2.5 x 2.3    pTis + (100) 2+ (100) LC - -
2  1.0 x 0.7    pTis# + (100) 2+ (50) LC 1+ -
3 1.5 ｘ 1.5 x 0.8    pT1a (LPM) + (100) 3+ (5) LC - -
4 3.6 x 1.1    pT1a (LPM) + (100)  - - 3+ (20) LC
5  1.3 x 0.7    pT1b (SM) + (100)  - - - -
6 1.4 x 1.0    pT1b (SM) -  - - - -
7  2.3 x 1.6    pT1b (SM) + (10) - - - -
8  1.8 x 0.5    pT1b (SM) + (100) - - - -
9 2.0 x 1.0 x 0.4    pT1b (SM) - - - - -
10 3.4 x 2.8    pT2 (MP) - - - - -
11  6.2 x 3.5    pT3 (AD) + (100) - - - -
IHC, immunohistochemistry; FISH, fluorescence in situ  hybridization; LC, large clustered signal; LPM,
lamina propria mucosae; SM, submucosa; MP, muscularis propriae; AD, adventitia; figures in parentheses,
% of positive cells. #The diagnosis was separated to pTis and pT1a by two versus  one.
Table 1. Pathological Classigfication and Results of IHC and FISH Analysis
 of Adenocarcinoma Arising in Barrett's Esophagus








Case 1. Endoscopic finding. An open ulcer in the lower esophagus. 
 
Fig. 2 
Case 1. Endoscopic mucosal biopsy. Tubules of atypical cells (A) are positive for p53 




Case 1. Resected esophagus. The ulcer scar was surrounded by fine granular mucosa 
(A). Representative histology of adenocarcinoma in situ (B). The adjacent sections were 
stained for ERBB2 (C). The region within the black rectangle corresponds to the field in 
Panel D. FISH shows that adenocarcinoma cells have clustered signals of ERBB2 (D). 
 
Fig. 4 
Case 3. Mucosal carcinoma with p53 overexpression (A) has small area of 
ERBB2-overexpressing cancer cells (B). The region within the black rectangle in Panel 
B is magnified in Panel C.  FISH analysis on the same field as Panel C shows that 
ERBB2-overexpressing cancer cells have the amplified ERBB2 gene, however the 
cancer cells overexpressing p53 but no ERBB2 have no amplified ERBB2 gene (D). 
 
Fig. 5 
Case 4. Mucosal carcinoma with p53 overexpression (A&B). Cancer cells with 
overexpression and amplification of EGFR occupy the right area of the picture (C&D). 
























IHC    IHC FISH IHC FISH
1 2.5 x 2.3    pTis + (100) 2+ (100) LC - -
2  1.0 x 0.7    pTis# + (100) 2+ (50) LC 1+ -
3 1.5 ｘ 1.5 x 0.8    pT1a (LPM) + (100) 3+ (5) LC - -
4 3.6 x 1.1    pT1a (LPM) + (100)  - - 3+ (20) LC
5  1.3 x 0.7    pT1b (SM) + (100)  - - - -
6 1.4 x 1.0    pT1b (SM) -  - - - -
7  2.3 x 1.6    pT1b (SM) + (10) - - - -
8  1.8 x 0.5    pT1b (SM) + (100) - - - -
9 2.0 x 1.0 x 0.4    pT1b (SM) - - - - -
10 3.4 x 2.8    pT2 (MP) - - - - -
11  6.2 x 3.5    pT3 (AD) + (100) - - - -
IHC, immunohistochemistry; FISH, fluorescence in situ  hybridization; LC, large clustered signal; LPM,
lamina propria mucosae; SM, submucosa; MP, muscularis propriae; AD, adventitia; figures in
parentheses, % of positive cells. #The diagnosis was separated to pTis and pT1a by two versus  one.
Table 1. Pathological Classigfication and Results of IHC and FISH Analysis
 of Adenocarcinoma Arising in Barrett's Esophagus
Case No. Size (cm) Depth of invasion
HER2 EGFR





